Salk scientists link bile acids and immune cell performance in liver cancer, finding that supplementing the bile acid UDCA—already a current treatment for liver disease—and inhibiting bile ...
Mirum Pharmaceuticals, Inc. today provided its preliminary and unaudited estimates for full-year 2024 net product sales, year-end cash balance, corporate updates, and full-year 2025 outlook. "2024 ...